Volume | 949,529 |
|
|||||
News | - | ||||||
Day High | 6.25 | Low High |
|||||
Day Low | 6.00 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Verve Therapeutics Inc | VERV | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
6.13 | 6.00 | 6.25 | 6.15 | 6.00 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
10,723 | 949,529 | US$ 6.14 | US$ 5,827,285 | - | 5.84 - 21.4199 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:43:04 | 2 | US$ 6.15 | USD |
Verve Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
513.42M | 83.62M | - | 11.76M | -200.07M | -2.39 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Verve Therapeutics News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VERV Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.21 | 6.56 | 5.84 | 6.11 | 1,133,153 | 0.0684 | 1.10% |
1 Month | 8.85 | 9.2316 | 5.84 | 7.22 | 1,143,414 | -2.57 | -29.06% |
3 Months | 10.95 | 19.34 | 5.84 | 11.27 | 1,312,600 | -4.67 | -42.66% |
6 Months | 12.17 | 20.12 | 5.84 | 11.96 | 1,473,104 | -5.89 | -48.41% |
1 Year | 16.07 | 21.4199 | 5.84 | 12.95 | 1,098,876 | -9.79 | -60.93% |
3 Years | 30.00 | 78.00 | 5.84 | 21.83 | 864,698 | -23.72 | -79.07% |
5 Years | 30.00 | 78.00 | 5.84 | 21.83 | 864,698 | -23.72 | -79.07% |
Verve Therapeutics Description
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. |